The most frequently occurring adverse reactions are somnolence (including drowsiness, tiredness, fatigue, daze) occurring in about 8% of patients and dry mouth occurring in about 5% of patients in clinical trials. These reactions are usually mild and disappear within a few days even if treatment is continued. The frequency of adverse reactions associated with the fixed dose combination of Cinnarizine + Dimenhydrinate in clinical trials and following spontaneous reports are as follows (Common >1/1000, <1/10, Uncommon >1/1,000, <1/100, Rare >1/10,000, <1/1,000, Very Rare <1/10,000): Blood and Lymphatic System Disorders:
Very Rare: Leucopenia, Thrombocytopenia, Aplastic Anemia.
Immune System Disorders:
Rare : Hypersensitivity Reactions (e.g., cutaneous reactions).
Nervous System Disorders:
Common: Somnolence, Headache. Uncommon: Paraesthesia, Amnesia, Tinnitus, Tremor, Nervousness, Convulsions.
Rare: Visual Disorders.
Common: Dry Mouth, Abdominal Pain. Uncommon: Dyspepsia, Nausea, Diarrhea.
Skin and Subcutaneous Tissue Disorders:
Uncommon: Perspiration, Rash. Rare: Photosensitivity.
Renal and Urinary Disorders:
Rare: Urinary Hesitancy.
In addition the following adverse reactions are associated with Cinnarizine and Dimenhydrinate: Dimenhydrinate:
paradoxical excitability (especially in children), worsening of existing angle-closure glaucoma, reversible agranulocytosis.
constipation, weight gain, tightness of the chest, cholestatic jaundice, extrapyramidal symptoms, lupus-like skin reactions, lichen planus.